X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11) 11
hematology (9) 9
index medicus (9) 9
cancer (7) 7
female (7) 7
leukemia, myeloid, acute - mortality (7) 7
middle aged (7) 7
oncology (7) 7
male (6) 6
survival (6) 6
adult (5) 5
aged (5) 5
bone marrow (5) 5
leukemia, myeloid, acute - drug therapy (5) 5
risk factors (5) 5
treatment outcome (5) 5
acute myelogenous leukemia (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
chemotherapy (4) 4
cytarabine - administration & dosage (4) 4
leukemia (4) 4
medical prognosis (4) 4
medicine (4) 4
mortality (4) 4
multidisciplinary sciences (4) 4
mutation (4) 4
patients (4) 4
prognosis (4) 4
remission (4) 4
acute myeloid leukemia (3) 3
cytarabine (3) 3
leukemia, myeloid, acute - diagnosis (3) 3
myeloid leukemia (3) 3
remission induction (3) 3
research article (3) 3
science (3) 3
stem cells (3) 3
stem-cell transplantation (3) 3
aged, 80 and over (2) 2
analysis (2) 2
anthracyclines (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
cancers and neoplasms (2) 2
cell line, tumor (2) 2
clinical trials (2) 2
cytarabine - adverse effects (2) 2
cytarabine - therapeutic use (2) 2
daunorubicin - administration & dosage (2) 2
daunorubicin - therapeutic use (2) 2
disease-free survival (2) 2
dose cytarabine (2) 2
drug dosages (2) 2
elderly-patients (2) 2
expression (2) 2
favorable prognosis (2) 2
fms-like tyrosine kinase 3 - genetics (2) 2
gene expression (2) 2
gene expression profiling (2) 2
gene mutations (2) 2
germany (2) 2
health aspects (2) 2
hematologic cancers and related disorders (2) 2
hematopoietic stem cell transplantation (2) 2
hemic and lymphatic diseases (2) 2
induction chemotherapy (2) 2
internal medicine (2) 2
kaplan-meier estimate (2) 2
kinases (2) 2
leukemia, myeloid, acute - genetics (2) 2
leukemias (2) 2
medical research (2) 2
medicine & public health (2) 2
medicine and health (2) 2
metastases (2) 2
metastasis (2) 2
microrna-expression signatures (2) 2
pathogenesis (2) 2
proteins (2) 2
research (2) 2
risk myelodysplastic syndrome (2) 2
standards (2) 2
survival analysis (2) 2
time factors (2) 2
transplants & implants (2) 2
5-azacytidine (1) 1
abridged index medicus (1) 1
acute leukaemia (1) 1
acute myeloid-leukemia (1) 1
adapter molecule mtss 1 (1) 1
adapter protein metastasis suppressor 1 (1) 1
adapters (1) 1
adolescent (1) 1
adults (1) 1
age (1) 1
age factors (1) 1
aged patients (1) 1
alemtuzumab (1) 1
alterations (1) 1
aml (1) 1
aml cell lines (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | AML | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | BONE-MARROW | CLASSIFICATION | FLT3 MUTATIONS | CYTARABINE | STEM-CELL TRANSPLANTATION | COMBINATION | ELDERLY-PATIENTS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9757, pp. 2000 - 2008
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2014, Volume 9, Issue 10, p. e109759
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2015, Volume 10, Issue 5, p. e0125783
The adapter protein metastasis suppressor 1 (MTSS1) is implicated as a tumor suppressor or tumor promoter, depending on the type of solid cancer. Here, we... 
MIM | HEPATOCELLULAR-CARCINOMA | METASTASIS | GENE | COLORECTAL-CANCER | MULTIDISCIPLINARY SCIENCES | MUTATIONS | EXPRESSION | CONTRIBUTES | REMISSION | MIM/MTSS1 | Gene Expression | Tumor Suppressor Proteins - metabolism | Prognosis | Humans | Leukemia, Myeloid, Acute - metabolism | Gene Expression Regulation, Leukemic - drug effects | Gene Expression Profiling | Neoplasm Proteins - metabolism | Leukemia, Myeloid, Acute - mortality | RUNX1 Translocation Partner 1 Protein | fms-Like Tyrosine Kinase 3 - genetics | Oncogene Proteins, Fusion - genetics | Tumor Suppressor Proteins - genetics | Chromosome Aberrations | Cell Line, Tumor | Microfilament Proteins - metabolism | Protein Kinase Inhibitors - pharmacology | Neoplasm Proteins - genetics | Core Binding Factor Alpha 2 Subunit - genetics | Microfilament Proteins - genetics | Karyotype | Cluster Analysis | Leukemia, Myeloid, Acute - genetics | Physiological aspects | Tumor suppressor genes | Research | Gene mutations | Protein kinase C | Pathogenesis | Leukemia | Colorectal cancer | Oncology | mRNA | Metastasis | Metastases | Ovarian cancer | Liver cancer | Fusion protein | Hematology | Myeloid leukemia | Adapters | Pharmacology | Gene expression | Patients | Medicine | Signaling | AML1 protein | Derepression | MicroRNAs | Medical prognosis | Cell lines | Stem cells | Mutation | Prostate cancer | Acute myeloid leukemia | Retinoic acid | Health informatics | Cancer
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2012, Volume 7, Issue 12, pp. e52695 - e52695
Introduction: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in... 
CONVENTIONAL CARE REGIMENS | PROGNOSTIC IMPACT | IDH2 MUTATIONS | 5-AZACYTIDINE | RECOMMENDATIONS | MULTIDISCIPLINARY SCIENCES | TET2 | RISK MYELODYSPLASTIC SYNDROMES | DNMT3A MUTATIONS | INDUCTION | CHRONIC MYELOMONOCYTIC LEUKEMIA | Humans | Middle Aged | Induction Chemotherapy | Male | Treatment Outcome | Consolidation Chemotherapy | Cytarabine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - toxicity | Feasibility Studies | Leukemia, Myeloid, Acute - mortality | Maximum Tolerated Dose | Pilot Projects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Daunorubicin - administration & dosage | Azacitidine - administration & dosage | Anthracyclines | Chemotherapy | Analysis | Oncology, Experimental | Clinical trials | Aged patients | Research | Standards | Cancer | Toxicity | Leukemia | Brain cancer | Oncology | Cardiovascular disease | Kinases | Randomization | Cytarabine | Daunorubicin | Consolidation | Safety engineering | DNA methylation | Bone marrow | Remission | Heart diseases | Drug dosages | Deoxyribonucleic acid--DNA | Medical research | Hematology | Myeloid leukemia | Feasibility studies | Patients | Survival | Constraining | White blood cells | Medicine | Medical prognosis | Mutation | Acute myeloid leukemia | Index Medicus | Deoxyribonucleic acid | DNA
Journal Article
Journal Article